Answers are grounded in this paper and cite their sources.
Drugs are challenging to remove from water due to their chemical stability, low biodegradability, and resistance to conventional water treatments. Thus, this work aimed to synthesize a niobium-based nanozeolite (Nb-nFAU) to remove the Escitalopram Oxalate drug (EsOx) from water, in continuous operation. Nb-nFAU was obtained by hydrothermal method, combining zeolite precursors and ammonium niobium(V) oxalate (10 wt.%). The Nb-nFAU was characterized by XRD, FEG–SEM with EDX, N2 porosimetry, DLS, and pHZCP. XRD identified faujasite, niobium pentoxide, and lueshite for Nb-nFAU. Moreover, SBET = 234.8 ± 1.9 m2 g−1, Vp = 0.121 ± 0.01 cm3 g−1, Dp = 13.7 ± 2.6 nm, ZP = −19.7 ± 2.5 mV, PDI = 0.67 ± 0.07, and pHZCP 7.06 were reported for Nb-nFAU. The experimental data were fitted by Clark, Thomas, and Yoon–Nelson models, which indicated high affinity between EsOx and Nb-nFAU. Nb-nFAU showed higher bed adsorption capacity (qbed = 8.79 mg g−1) than pristine nanozeolite, nFAU (qbed = 6.37 mg g−1), and higher breakthrough time (53.11 min versus 34.77 min). nFAU and Nb-nFAU showed qmax = 82.5 and 92.4 mg g−1, respectively. Therefore, the incorporation of Nb proved to enhance the adsorption capacity of nanozeolites, being useful as a starting point for scale-up studies.
No takes yet. Share an insight, caveat, or question.
Oviedo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: